Re: Prostate cancer progression and survival in BRCA2 mutation carriers.

摘要

The authors compared cancer-specific survival, disease stage, and tumour grade between prostate cancer (PCa) patients carrying the Icelandic BRCA2 999del5 founder mutation and non-carriers. Cross-referencing of all PCa patients who were listed in the Icelandic cancer registry with male relatives of breast cancer patients revealed 596 PCa patients, in 527 of whom mutation status could be evaluated. Thirty patients (5.7%) carried the mutation. Each carrier was matched to two control patients carrying the wild-type gene on year of birth (within 7 yr) and year of diagnosis (within4yr). Compared to matched controls, carriers were younger at diagnosis (69.0 vs. 74.0 yr), had more advanced tumour stages (79.3% vs. 38.6% grade 3-4), and were more often diagnosed with metastatic disease at diagnosis (55.2% vs. 24.6%). Moreover, median cancer-specific survival was 2.1 yr versus 12.4 yr for non-carriers. After adjustment for age, year of diagnosis, stage, and grade, carrying the BRCA2 999del5 mutation was still associated with an increased risk of dying from PCa. The authors conclude that the Icelandic BRCA2 999del5 mutation is strongly associated with a highly aggressive form of PCa.